Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or New Jersey for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to New Jersey only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. New Jersey (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bhavesh Balar (NPI 1134113376)

Field	Value
Entity Type	Individual
Organization	Bhavesh Balar
Address	326 Professional View Dr
City	Freehold
State	NJ
ZIP	07728
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 2, 2005

Payer Source	Total Paid
Medicare	$4.2M
Medicaid	$0

Key Findings

This provider is effectively single‑payer at the beneficiary level: Total Medicare revenue is $4.2M and there is no Medicaid billing on file, indicating the provider’s Medicare activity dominates its public payer footprint. The NPI was enumerated 2005-09-02 (~21 years ago), consistent with a long-tenured practice that has built a Medicare-centric patient base over time.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 62.7% of the provider’s Medicare revenue, driven primarily by J9271 (34.0% of Medicare revenue), J9299 (21.4% of Medicare revenue), and J0897 (7.3% of Medicare revenue). This concentration signals that a small set of high-volume injectable oncology drugs is responsible for most of the practice’s Medicare dollars.

The code mix and volumes indicate an oncology-focused infusion operation: very large claim counts for immunotherapy agents (J9271: 32.2K claims; J9299: 36.2K claims) together with chemotherapy/infusion procedure codes (96413, 96365, 96367) point to routine administration of IV cancer therapies in an outpatient/clinic setting. Ancillary lab and venipuncture activity (85025 and 36415, each ~3.6K claims) further support a clinic that handles frequent infusion visits and pre/post infusion monitoring.

Unit-payment dynamics show the business model relies on very high drug administration volumes rather than high per-unit reimbursements: J9271 is paid $43 avg/claim and J9299 $24 avg/claim, yet each contributes substantial Medicare revenue due to their very large claim counts. Several biologic and supportive agents (e.g., J1437 paid $17 avg/claim with 13.8K claims) reinforce a throughput-driven infusion practice.

Competitive standing by code: the provider ranks substantially above national norms on key oncology drugs and services — J9271 ranks #99 of 1841 (95th percentile; notably above typical national volume), J9299 ranks #43 of 505 (92th percentile; notably above typical national volume), and J1437 ranks #10 of 581 (98th percentile; extreme outlier, far above typical national volume for this code). High percentiles on administration and E/M codes (e.g., 99214 ranks #1243 of 479517, 100th percentile; labeled extreme outlier) indicate the practice is a major national participant for several high-impact items.

Several codes are flagged as statistical outliers, underscoring atypical volume patterns: in addition to J1437’s “extreme outlier” status, 96367 (additional IV infusion) is described as a 99th percentile extreme outlier and 99215/99214 are described as 100th percentile extreme outliers. At the same time, multiple supportive care and biosimilar codes (J1569, Q5111, Q5119) are described as typical or unremarkable in volume, suggesting the outlier behavior is concentrated in a subset of oncology drug administrations.

Operational implications for payer contracting and network strategy: a practice this concentrated in immunotherapy and infusion services will be sensitive to unit-price negotiation on high-volume agents and to pathways that shift site-of-care for IV infusions. Given the absence of Medicaid billing, payer strategies and network decisions should focus primarily on Medicare arrangements and commercial counterparts that mirror the Medicare infusion mix.

Clinical-service detail supports a high-touch outpatient infusion model: E/M codes for established patients (99214: 2K claims; 99215: 750 claims) alongside inpatient follow-up codes (99233, 99223) and initiation/continuation infusion codes (G0498, 96413) indicate the provider manages both office-based and hospital/observation encounters tied to chemotherapy care. This pattern is consistent with a hematology/oncology physician practice that combines clinic infusions, inpatient follow-up, and routine procedural support services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

58 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	32,200	$40	$1.4M
J9299	Injection, nivolumab, 1 mg	36,240	$20	$869.8K
J0897	Injection, denosumab, 1 mg	16,500	$20	$297K
J1437	Injection, ferric derisomaltose, 10 mg	13,800	$20	$234.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,030	$100	$207.1K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	4,270	$40	$153.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	750	$150	$109.5K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	910	$110	$98.5K
J1627	Injection, granisetron, extended-release, 0.1 mg	19,300	$10	$96.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	850	$110	$95.7K

Showing 1–10 of 58

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 58 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. New Jersey Distribution

Bhavesh Balar — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — New Jersey

Full comparison — all codes billed, vs. state median

58 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	50	10,650	$40	$580.7K
J9299	1	10	23,410	$20	$565.3K
J1569	2	10	2,890	$40	$111.3K
Q5119	5	10	3,620	$20	$98.7K
J0897	15	380	3,060	$20	$87.8K
J1437	1	30	4,000	$20	$78.6K
Q5111	9	50	580	$110	$76.6K
J1627	1	10	5,900	$1	$33.2K
J3490	1	120	70	$230	$30.2K
Q5106	9	50	3,820	$10	$30K

Showing 1–10 of 58

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bhavesh Balar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Glen Gejerman	NJ	Radiation Oncology Physician	$6.5M	$0
Kenneth Nahum	NJ	Hematology & Oncology Physician	$3.2M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
May Abdo-matkiwsky	NJ	Hematology & Oncology Physician	$2.6M	$0
Denis Fitzgerald	NJ	Hematology & Oncology Physician	$2.3M	$0
Gurpreet Lamba	VT	Hematology & Oncology Physician	$2.2M	$0
Jeffrey Silberberg	NJ	Hematology & Oncology Physician	$2M	$0
Victor Aviles	MA	Hematology & Oncology Physician	$1.8M	$0
James Xu	MD	Hematology & Oncology Physician	$1.6M	$0
Jaffar Hilli	MO	Hematology & Oncology Physician	$1.6M	$0

Nearby Providers

Other providers in the same ZIP code as Bhavesh Balar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Golden Years Care LLC	NJ	Adult Day Care Clinic/Center	$0	$49.5M
Centrastate Medical Center, Inc	NJ	General Acute Care Hospital	$0	$47.4M
Collaborative Support Program Of New Jersey, Inc	NJ	Community/Behavioral Health Agency	$0	$12.2M
Community Care Inc	NJ	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$11.3M
Tender Smiles 4 Kids Of Monmouth, LLC	NJ	Pediatric Dentistry	$0	$9.5M
Hisham El-kadi	NJ	Rheumatology Physician	$3M	$0
Elena Ng	NJ	Ophthalmology Physician	$2.4M	$0
Karabi Sinha	NJ	Anatomic Pathology & Clinical Pathology Physician	$1.9M	$0
James Fischkoff	NJ	Rheumatology Physician	$1.1M	$0
Jae Lee	NJ	Radiation Oncology Physician	$970.3K	$0

Bhavesh Balar — Billing Profile & Reimbursement Data

Sign up for Bhavesh Balar — Billing Profile & Reimbursement Data policy alerts

Bhavesh Balar — Billing Profile & Reimbursement Data

Sign up for Bhavesh Balar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References